Tag: pharmaceuticals
-
Clinical Trial Underway Testing Influenza Vaccine Patch
A clinical trial has begun testing a commercially-available flu vaccine administered with a painless patch device against conventional syringe injection delivery.
-
Allergy Antibody Biotech Gains $40M in New Funds
A biotechnology enterprise creating engineered antibodies to treat severe food allergies is raising $40 million in its second venture financing round.
-
Collaboration Developing Microbiome Boost to Cancer Immunotherapy
A biotechnology company creating treatments that work with gut microbes is partnering with M.D. Anderson Cancer Center on more effective cancer immunotherapies.
-
New Venture Funds to Back Life Science, Tech Start-Ups
Three new venture funds are seeking to invest up to $6.3 billion in start-up companies with advances in life sciences, health care, energy, and information technologies.
-
Real-World Data Shown to Match Eye Disease Trial Results
Research findings show data in patients’ electronic health records can be collected and analyzed to replicate results from late-stage clinical trials of an eye disease biologic drug.
-
Nasal Spray Vaccine Shown to Stop Gonorrhea Infections
A vaccine against gonorrhea given as a nasal spray is shown to generate protective immune responses in lab mice of both sexes, and in females similar to an intravaginal vaccine.
-
Infographic – 2022 Biotech Venture Funding Weakens
Venture funds for new U.S. biotechnology and pharmaceutical companies declined from historical highs in 2022, but a closer look reveals even more signs of financial tightening.
-
CEPI Assessing Advanced RNA Nanoparticle Vaccine
An international health organization is evaluating a new type of vaccine made with biodegradable RNA nanoparticles to help head off future viral pandemics.
-
Nanotech Enzyme Process Boosts T-Cell Cancer Therapies
A bioengineering team devised techniques for feasibly adding cancer-killing enzymes to engineered immune cells that in lab mice kill solid-tumor and blood cancer cells.
-
BioNTech to Provide Personal Cancer Immunotherapies in UK
The biotechnology company BioNTech SE is partnering with the U.K. government to provide up to 10,000 personalized cancer immunotherapy treatments by 2030.